MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$36,975K
EPS
-$0.4
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue-License
NaN -26,706* NaN NaN
Restructuring
NaN 0* 0 0
Total revenue
127,199 NaN 164,859 114,449
In-process research and development
NaN 0* 0 0
Product
NaN 3,583* NaN NaN
License
NaN -1,028* NaN NaN
Total revenue-Product
NaN 156,394* NaN NaN
Cost of goods sold
1,950 2,554 1,585 1,521
Research and development
57,094 57,870 51,890 49,362
Selling, general and administrative
80,254 101,695 86,453 76,216
Royalty expense
24,816 NaN NaN NaN
Total operating expenses
164,114 162,119 139,928 127,099
Operating loss
-36,915 -32,431 24,931 -12,650
Interest income
2,584 2,592 3,047 3,287
Interest expense
2,300 2,294 2,751 2,846
Other (expense) income, net
-91 11,068 487 -526
Total other income, net
193 11,366 783 -85
Loss from continuing operations before income tax
-36,722 -21,065 25,714 -12,735
Income tax benefit (provision) on continuing operations
-120 921 8 20
Loss from continuing operations, net of tax
-36,602 -21,986 25,706 -12,755
Loss from discontinued operations, net of tax
-500 24,715 0 0
Unrealized gain (loss) on defined benefit pension plan
NaN -219 NaN NaN
Net gain
-37,102 2,729 25,706 -12,755
Foreign currency translation gain (loss)
447 -243 -284 268
Unrealized loss on marketable debt securities
-320 -111 42 -237
Comprehensive gain
-36,975 2,594 25,464 -12,724
Basic EPS
-0.4 0.029 0.29 -0.14
Diluted EPS
-0.4 0.034 0.28 -0.14
Basic Average Shares
91,868,862 90,315,235 89,230,420 88,945,624
Diluted Average Shares
91,868,862 76,927,095 102,618,560 88,945,624
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive gain-$36,975K (11.94%↑ Y/Y)Foreign currencytranslation gain (loss)$447K (165.16%↑ Y/Y)Net gain-$37,102K (10.00%↑ Y/Y)Unrealized loss onmarketable debt securities-$320K (-315.58%↓ Y/Y)Loss from continuingoperations, net of tax-$36,602K (11.22%↑ Y/Y)Loss fromdiscontinued operations, net...-$500K Income tax benefit(provision) on continuing...-$120K (-407.69%↓ Y/Y)Interest income$2,584K (-31.91%↓ Y/Y)FILSPARI$105,152K Tiopronin Products$19,340K Loss from continuingoperations before income...-$36,722K (10.84%↑ Y/Y)Total other income,net$193K (-87.02%↓ Y/Y)Product$124,492K (9835.51%↑ Y/Y)License$2,707K (-20.99%↓ Y/Y)Interest expense$2,300K (-19.50%↓ Y/Y)Other (expense)income, net-$91K (-116.58%↓ Y/Y)Operating loss-$36,915K (13.50%↑ Y/Y)Total revenue$127,199K (55.63%↑ Y/Y)Total operatingexpenses$164,114K (31.92%↑ Y/Y)Selling, general andadministrative$80,254K (10.18%↑ Y/Y)Research and development$57,094K (21.76%↑ Y/Y)Royalty expense$24,816K Cost of goods sold$1,950K (-58.32%↓ Y/Y)

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics, Inc. (TVTX)